Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 1—January 2021
Research Letter

Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States

Connie A. HaleyComments to Author , Patricia Macias, Supriya Jasuja, Betsy A. Jones, Marie-Claire Rowlinson, Roshni Jaimon, Pennelyn Onderko, Elaine Darnall, Maria E. Gomez, Charles Peloquin, David Ashkin, and Neela D. Goswami
Author affiliations: University of Florida, Gainesville, Florida, USA (C.A. Haley, M.E. Gomez, D. Ashkin); Cook County Department of Public Health, Chicago, Illinois, USA (P. Macias, S. Jasuja, R. Jaimon, P. Onderko); Florida Department of Health, Jacksonville, Florida, USA (B.A. Jones, M.-C. Rowlinson, D. Ashkin); Illinois Department of Public Health, Springfield, Illinois, USA (E. Darnall); University of Florida College of Pharmacy, Gainesville (C. Peloquin); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (N.D. Goswami)

Main Article

Table 2

Laboratory, electrocardiographic and clinical monitoring data for patient treated for XDR TB, United States*

Date AST, IU/L ALT, IU/L ALP, IU/L Creatinine, mg/dL Magnesium, mg/dL Hgb, g/dL Leukocyte, × 109/L Plt, × 109/L QTc, msec Notes
Initial treatment with rifampin, isoniazid, pyrazinamide, and ethambutol
2019 Aug 2
 67
 86
 221
 0.66
 NT
 10.4
 3.97
 272
 NT
 None
Bridging regimen of bedaquiline, linezolid, moxifloxacin, cycloserine, clofazimine, and ethambutol
2019 Oct 3 53 62 121 0.64 1.9 12.7 5.4 278 402 None
2019 Oct 15
 73
 70
 147
 NT
 NT
 12.6
 5.3
 243
 NT
 None
BPaL regimen
2019 Oct 21 57 71 135 0.94 1.9 12.9 3.9 257 413 None
2019 Nov 11 40 53 113 1.01 1.9 12.3 4.9 237 426 Pantoprazole started for brief nausea
2019 Dec 2 52 63 118 0.77 1.9 10.7 4.3 289 421 None
2019 Dec 16 NT NT NT NT NT 11.2 4.7 267 NT None
2020 Jan 6 58 74 107 0.80 2.0 12.5 5.1 271 422 None
2020 Feb 3 36 39 89 0.76 1.9 12.2 4.2 258 429 None

*Initial treatment period was August 5–September 9, 2019; bridging regimen period October 7–21, 2019; BPaL treatment period October 21, 2019–April 21, 2020. ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BPaL, bedaquiline, pretomanid, and linezolid; Hgb, hemoglobin; leukocyte, leukocyte count; NT, not tested; Plt, platelet; QTc, corrected QT interval.

Main Article

Page created: October 28, 2020
Page updated: December 21, 2020
Page reviewed: December 21, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external